ImmunityBio Sinks on Profit-Taking Despite 200% Surge, Glioblastoma Data in Focus | MarketWire
ImmunityBio's stock cools after a massive rally, as glioblastoma data and investor profit-taking weigh on sentiment. Here's what it means for biotech investors.